Skip to main content
WADA Banned 16 views

GHRP-6

Growth hormone secretagogue with strong appetite stimulation

GHRP-6 molecular structure

WADA BANNED - Prohibited in competitive sports as growth hormone releasing peptide

Overview

GHRP-6 (Growth Hormone Releasing Peptide-6) is one of the first synthetic growth hormone secretagogues developed, consisting of six amino acids that stimulate growth hormone release through ghrelin receptor (GHS-R1a) activation. Research demonstrates GHRP-6 produces potent GH stimulation but is characterized by significant appetite increase due to its strong ghrelin-mimetic effects. The peptide also elevates cortisol and prolactin levels more than newer, more selective alternatives. Despite these characteristics, GHRP-6 effectively promotes muscle growth, fat metabolism, improved recovery, and enhanced sleep quality through optimized GH secretion. Studies show additive effects when combined with GHRH analogs. GHRP-6 has been used extensively in research settings to study growth hormone physiology and the ghrelin system. The peptide requires multiple daily subcutaneous injections and is typically administered on an empty stomach to maximize GH response. While effective for GH stimulation, the pronounced hunger effects have led many researchers and users to prefer more selective alternatives like Ipamorelin or Hexarelin.

Last reviewed: 2026-08-18

Identity & Aliases

Also known as

Growth hormone-releasing peptide-6His-D-Trp-Ala-Trp-D-Phe-Lys-NH2GHRP-6 hexapeptide

Status: Research compound - Growth hormone releasing peptide

CAS87616-84-0
PubChem5486806

Full composition (formula, molecular weight, sequence) in Quick Facts →

Research Areas

Growth hormone secretion / secretagoguesGhrelin (GHS-R1a) receptor pharmacologyAppetite regulationGH-deficiency diagnostics

Available Evidence

Human

GHRP-6 has been used in clinical research settings to probe GH physiology: for example, a 1995 study showed additive GH responses when GHRH, GHRP-6, and pyridostigmine were combined in normal and obese subjects. It is not an FDA-approved drug for any indication.

Animal

Rodent studies established GHRP-6 as a potent GH secretagogue acting through the ghrelin receptor (GHS-R1a), with marked orexigenic (appetite-stimulating) effects.

In Vitro

Cell-based assays confirm GHRP-6 binds and activates the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor).

Uncertain

Body-composition, recovery, and performance claims for GHRP-6 as a self-administered peptide are not supported by clinical trials; elevations in cortisol and prolactin and strong hunger are reported effects that make it poorly suited to therapeutic use.

Key Studies & Findings

1 studies
Clinical1995

Combined administration of GHRH, GHRP-6, and pyridostigmine produced additive GH responses in normal and obese subjects, demonstrating GHRP-6's GH-releasing activity in humans.

Benefits & Effects

8 documented

Appetite stimulation

anecdotal

Enhanced strength

anecdotal

Better sleep quality

anecdotal

Muscle recovery

anecdotal

Growth hormone release

anecdotal

Improved body composition

anecdotal

Cardioprotection: Prevents doxorubicin cardiomyopathy, preserves LV function

clinical

Multiple Organ Protection: 50-85% reduction in hepatic/intestinal damage

clinical

Side Effects & Safety

7 reported

ACTH/Cortisol elevation

Mild

Appetite stimulation

Mild

Very strong appetite stimulation

MildUncommon

Bloating

MildUncommon

Tingling

MildUncommon

Rare prolactin increase

SevereRare

Mild side effect

MildVery common Reversible

Onset: Immediate

Management: Expected pharmacologic effect

Dose-dependent

Limitations & Open Questions

Human data come mainly from short physiological studies of GH secretion, not from trials of therapeutic or performance outcomes. No long-term efficacy or safety trials exist; appetite stimulation, cortisol/prolactin effects, and the need for frequent injections are major caveats.

Pharmacology

Short-acting hexapeptide agonist of the ghrelin/GHS-R1a receptor; in research use it is given by subcutaneous injection to stimulate pulsatile GH release. Published human pharmacokinetic data are limited; no approved indication or dose exists.

Reported Research Dosing

Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.

100-300 mcg 2-3x/day

Route: SC
Half-life: ~2.5 hours

Frequently Asked Questions

Is GHRP-6 FDA approved?

No. GHRP-6 is an unapproved research peptide.

Why does GHRP-6 cause hunger?

It activates the ghrelin receptor (GHS-R1a), the same receptor targeted by the 'hunger hormone' ghrelin, which stimulates appetite.

Is GHRP-6 evidence-based for muscle growth?

It reliably raises GH in short-term physiology studies, but no clinical trials demonstrate muscle or performance benefits from GHRP-6 use.

Research Citations

1
The Ghrelin Analog GHRP-6, Delivered Through Aquafeeds, Modulates the Endocrine and Immune Responses of

Leandro Rodríguez-Viera, Anyell Caderno, Rebeca Martinez, Gonzalo Martinez-Rodríguez, Milagrosa Oliva (2025)

4

Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency.

Pombo M, Leal-Cerro A, Barreiro J, Peñalva A, Peino R, Mallo F, Dieguez C, Casanueva FF (1996)

5
[D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle.

Yu AP, Pei XM, Sin TK, Yip SP, Yung BY, Chan LW, Wong CS, Siu PM (2015)

+ 46 more citations

Related Resources

Quick Facts

Formula

C46H56N12O6

Molecular Weight

873.01

Sequence

His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Mechanism

Potent GH releaser with appetite enhancement

Safety Information

Research compound only. Limited human safety data available.

View All Peptides